SCHEMBL4890688

SCHEMBL4890688

CCOC(=O)C(C=CC(=O)OC)=C(C)N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 3/20 0.45
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
NPSR1 Q6W5P4 2/20 0.39
GLO1 Q04760 1/20 0.39
ALOX15 P16050 1/20 0.38
MAPT P10636 5/20 0.36
ALDH1A1 P00352 3/20 0.35
CYP2D6 P10635 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RAB9A P51151 1/20 0.35
GFPT1 Q06210 1/20 0.35
LMNA P02545 2/20 0.34
HSD17B10 Q99714 1/20 0.34
KDM4E B2RXH2 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14870465 1.00 HCAR2 (0.45) HCAR2KEAP1NFE2L2NPSR1GLO1
SCHEMBL948834 0.89 HCAR2 (0.52) HCAR2NPSR1GLO1ALOX15MAPT
SCHEMBL29786598 0.84 GLO1 (0.42) HCAR2NPSR1GLO1ALOX15MAPT
SCHEMBL5083093 0.82 HCAR2 (0.41) HCAR2KEAP1NFE2L2NPSR1GLO1
SCHEMBL5083089 0.82 HCAR2 (0.41) HCAR2KEAP1NFE2L2NPSR1GLO1
SCHEMBL12571368 0.80 MAPT (0.40) HCAR2KEAP1NFE2L2NPSR1GLO1
SCHEMBL31172532 0.80 GAA (0.38) HCAR2KEAP1NFE2L2NPSR1ALOX15
SCHEMBL1970792 0.80 MAPT (0.40) HCAR2KEAP1NFE2L2NPSR1GLO1
SCHEMBL12913210 0.79 GLO1 (0.41) HCAR2NPSR1GLO1ALOX15MAPT
SCHEMBL7375216 0.77 HCAR2 (0.56) HCAR2KEAP1NFE2L2NPSR1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180193315-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC (US) 2018-07-12 US disclosed
US-20180071262-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC. (US) 2018-03-15 US disclosed
US-20160235716-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC. (US) 2016-08-18 US disclosed
WO-2016044770-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC. (US) 2016-03-24 WO disclosed
US-20080200448-A1 reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate ASTRAZENECA AB (SE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235716-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE KAT2B, HDAC1, HDAC9 HCAR2 748/4885KEAP1 497/4885NFE2L2 2125/4885
US-20080200448-A1 reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate P2RY12, P2RY13, P2RY11 HCAR2 180/4885KEAP1 3355/4885NFE2L2 3668/4885
US-20180193315-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE KAT2B, HDAC1, KAT2A HCAR2 711/4885KEAP1 398/4885NFE2L2 1694/4885
US-20180071262-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE KAT2B, HDAC1, HDAC9 HCAR2 748/4885KEAP1 497/4885NFE2L2 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.